Flualprazolam

8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine

Flualp, F-Alp, 2'-Fluoro-Alprazolam

Psychoactive Class

Depressant Anxiolytic GABAergic Muscle Relaxant

Chemical Class

Flualprazolam is a synthetic depressant of the triazolobenzodiazepine class and a fluorinated analog of alprazolam (Xanax)¹. It first appeared on the research chemical market in 2017¹, though its developmental origins remain unclear. Flualprazolam is notably more potent than alprazolam², producing effects at lower doses with a relatively rapid onset. It has reportedly been deceptively sold as alprazolam despite differing in substantive ways²¹, posing significant harm reduction concerns.

Dosage & Duration

Dosage

Threshold~0.05 mg

Light0.1-0.25 mg

Moderate0.25-0.5 mg

Strong0.5-1 mg

Heavy1+ mg

Reported to be more potent by weight than alprazolam, with user estimates ranging from roughly 1.5 to 5 times stronger; onset of effects is relatively rapid.

Duration

Onset10-30 minutes

Peak1-2 hours

Offset2-6 hours

After Effects6-24 hours

Total5-8 hours

Subjective Effects

The experience is dominated by heavy sedation, anxiety relief, and muscle relaxation, with a relatively rapid onset and greater potency than alprazolam. Central nervous system depression dampens feelings and perceptions rather than altering them, producing a calm, blunted state that can progress into sleep at higher doses. Memory of the period after ingestion frequently becomes unreliable, and compulsive redosing during these gaps is a recognized hazard.

Physical

Pronounced muscle relaxation and a heavy, sedated body feeling are the primary physical effects, often accompanied by dizziness, impaired coordination and reaction time, and slowed breathing at higher doses. Prolonged fatigue and hangover-like lethargy can persist after the main effects subside.

Sedation

Muscle relaxation

Uncomfortable

Dizziness HeadachesMuscle weakness

Cognitive

The headspace is calm, quieted, and disinhibited, with reduced anxiety and dampened emotional response. Thought slows noticeably, and confusion and anterograde amnesia become prominent at moderate to high doses; paradoxical aggression, irritability, and outbursts of anger have also been reported.

Suppressions

Cognitive effects are dominated by suppression, consistent with reduced information flow between neurons and general dampening of feelings and perceptions.

Thought decelerationConfusion

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Flualprazolam acts as a positive allosteric modulator at the GABA-A receptor via the benzodiazepine binding site, enhancing the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).³⁴ This mechanism is consistent with its classification as a triazolobenzodiazepine.³ It appears to be more potent by weight than its parent compound alprazolam, from which it is derived as the 2'-fluoro substituted analog.³⁵

Pharmacokinetics

Limited pharmacokinetic data is available for flualprazolam.⁵ It is reported to have a significantly longer elimination half-life than alprazolam, though specific values have not been well characterized.⁵

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholGHB/GBLOpioidsTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

DiphenhydraminePCP

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

DXMKetamineMXE

TripSit

Tolerance

Full Tolerance

Tolerance to sedative-hypnotic effects can emerge quickly, often after only several days of uninterrupted use. Reports suggest flualprazolam can sharply accelerate cross-tolerance with benzodiazepines, so limiting use to short periods is strongly advised.

Cross Tolerance

Benzodiazepines, Other GABAergic depressants

Baseline Reset

Tolerance generally returns to baseline within 7-14 days after cessation. However, following prolonged or intensive use, this recovery period may extend significantly longer in proportion to the duration and intensity of prior consumption.

Harm Potential

Addiction & Dependence

Psychological

High

Considered highly addictive with a high potential for abuse.⁶ The short-lasting euphoric effects (1-2 hours) encourage compulsive redosing while still intoxicated. Rapidly increases benzodiazepine cross-tolerance, making short-term use strongly advised.

Physical

Extremely High

Regular use leads to physical dependence with potentially life-threatening withdrawal. Discontinuation after prolonged use can cause dizziness, physical weakness, tremors, sleep disturbances, sweating, nausea, hallucinations, depression, and seizures. Gradual dose tapering under medical supervision is necessary; abrupt cessation is dangerous.

Psychosis Risk

Paradoxical reactions including aggression, violent behavior, and suicidal behavior occur rarely in the general population (below 1% incidence). These effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and those on high-dosage regimens. Hallucinations may occur as a withdrawal symptom.

Seizure Risk

Has anticonvulsant properties during use (seizure suppression). However, there is an increased risk of seizures following discontinuation, particularly after heavy or long-term use. Paradoxically, some benzodiazepines can cause seizures in epileptics. Substances that lower seizure threshold should be avoided during withdrawal.

History & Culture

Flualprazolam was first synthesized in 1976 as part of broader benzodiazepine research,⁶ representing the triazolo analog of fludiazepam and structurally related to alprazolam as its 2'-fluoro derivative. Despite its early synthesis, the compound was never developed…

Legality

International

UN Convention on Psychotropic Substances 1971 (Schedule II) - added March 2020

By Country

United StatesSchedule I

Designated as a Schedule I controlled substance effective January 23, 2023.¹¹ Classified as having high potential for abuse with no currently accepted medical use in treatment.¹¹

PolandIV-P group

Placed under the IV-P group of controlled psychotropic substances as of March 11, 2021.⁹ Ownership, possession, and sale are prohibited under Polish law.

United KingdomPsychoactive Substances Act 2016

Controlled under the blanket ban of the Psychoactive Substances Act rather than scheduled under the Misuse of Drugs Act.¹⁰ Production, supply, and possession with intent to supply carry criminal penalties.¹⁰

GermanyAnlage II BtMG

Listed under Anlage II of the Betäubungsmittelgesetz (Narcotics Act) as of January 21, 2021.⁸ This schedule designates it as a marketable controlled narcotic requiring prescription authorization.

TurkeyControlled substance

Classified as a controlled drug under national drug legislation. Possession, production, supply, and importation are all prohibited.

References

Source Pages

Citations

Suggest an edit